Cardiovascular and thromboembolic medicines
Research activity includes oral formulations associated with cardiovascular disease management and anticoagulant therapy, with attention to agents used in heart failure, lipid lowering, and thrombosis prevention.
- Apixaban
- Sacubitril/valsartan
- Rosuvastatin/ezetimibe
- Ezetimibe/atorvastatin
- Edoxaban
The sponsor’s portfolio in this area reflects interest in treatments for atrial fibrillation, hypercholesterolemia, and broader cardiometabolic risk control.
Metabolic and endocrine therapies
Clinical research also covers medicines used in type 2 diabetes and related metabolic conditions, including combination products that support glycemic control and renal-cardiovascular risk management.
- Dapagliflozin
- Dapagliflozin/metformin
- Linagliptin
- Linagliptin/metformin
- Canagliflozin
These studies indicate a sustained focus on antihyperglycemic agents and fixed-dose combinations used in long-term metabolic disease treatment.
Neurology and psychiatry
Investigational work includes therapies relevant to neuropathic pain and mental health, spanning agents used for sensory symptoms and mood-related disorders.
- Pregabalin
- Vortioxetine
This area highlights interest in both central nervous system treatment and symptomatic relief for chronic neurological and psychiatric conditions.
Gastrointestinal and allergy treatments
The sponsor also studies medicines used for digestive disorders and allergic disease, including treatments aimed at symptom control in common outpatient conditions.
- Loperamide
- Bilastine
These trials cover antidiarrheal and antihistamine therapy, reflecting interest in supportive care and routine symptom management.
Healthy volunteer bioequivalence research
All funded studies are conducted in healthy volunteers and focus on bioavailability and bioequivalence assessment for oral solid dosage forms.
- Comparative formulation studies
- Generic medicine development
- Reference product comparison
Research activity is concentrated in Spain, with trials supporting the development of therapeutic alternatives across multiple medicine classes.
